Working... Menu

A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients (DIRECT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00926562
Recruitment Status : Completed
First Posted : June 23, 2009
Last Update Posted : June 27, 2011
Information provided by:
Chinese PLA General Hospital

Brief Summary:
The investigators intend to find out which contrast agent has less kidney toxicity in renal impaired patients undergoing cardiac angiography or percutaneous coronary intervention (PCI).

Condition or disease Intervention/treatment Phase
Kidney Failure, Chronic Drug: Iopromide (Ultravist) Drug: Iodixanol (Visipaque) Phase 4

Detailed Description:
In the diagnosis and treatment of coronary heart disease, patients should undergo cardiac angiography or percutaneous coronary intervention (PCI). In those procedures, the investigators should use the contrast media, and it may cause kidney toxicity especially in the patients with chronic renal insufficiency.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 592 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Double-blinded Comparison of Iopromide and Iodixanol in Renally Impaired Patients Undergoing Cardiac Catheterization
Study Start Date : February 2009
Actual Primary Completion Date : December 2010
Actual Study Completion Date : May 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Iopromide
Drug: Ultravist 370 mgl/ml, injection of intra-artery during cardiac interventional operation
Drug: Iopromide (Ultravist)
Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM
Other Name: Ultravist

Active Comparator: Iodixanol
Drug: Visipaque 320 mgl/ml, injection of intra-artery
Drug: Iodixanol (Visipaque)
Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM
Other Name: Visipaque

Primary Outcome Measures :
  1. Proportion of patients exhibiting a relative increase in serum creatinine >= 50% from baseline. [ Time Frame: day 3 postreatment ]

Secondary Outcome Measures :
  1. Proportion of patients developing acute renal failure. [ Time Frame: day 30 postreatment ]
  2. Incidence of a postdose SCr increase ≧25%, a postdose SCr increase ≧1mg/dL, a postdose SCr increase ≧0.5mg/dL, a postdose eGFR decrease ≧25% [ Time Frame: days 3 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years old or older
  • Plan to undergo Cardiac Catheterization
  • Signed ICF
  • eGFR: 30~59 mL/min/1.73m2

Exclusion Criteria:

  • Pregnancy
  • Under dialysis
  • Conditions interfering with Cardiac Catheterization
  • Participation in other trials
  • Allergic to X-ray contrast media
  • Administration of any investigational drug within the previous 30 days
  • Intra-arterial or intravenous administration of iodinated contrast medium from 7 days before to 72 hours after the administration of study drug
  • Left ventricular ejection fraction (LVEF) less than 30% by ultrasound examination
  • Intake of any nephrotoxic medications 24 hours before or after the administration of study drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00926562

Layout table for location information
China, Beijing
Beijing CHAO-YANG Hospital
Beijing, Beijing, China, 100020
General Hospital of Armed Police Forces
Beijing, Beijing, China, 100039
Peking University Third Hospital
Beijing, Beijing, China, 100191
Beijing Shi Jing Shan Hospital
Beijing, Beijing, China, 10040
Beijing Hospital
Beijing, Beijing, China, 100730
Chinese PLA general hospital
Beijing, Beijing, China, 100853
China, Henan
Henan Provincial People's Hospital
Zhengzhou, Henan, China, 450003
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450052
China, Hubei
Wuhan Asia Heart Hospital
Wuhan, Hubei, China, 430022
China, Hunan
The Second Hospital of Xiangya
Changsha, Hunan, China, 410013
China, Jilin
China-Japan Union Hospital of Jilin University
Changchun, Jilin, China, 130033
China, Jinlin
The First Hospital of Jilin University
Changchun, Jinlin, China, 130021
China, Shanghai
Shanghai First People's Hospital
Shanghai, Shanghai, China, 200080
Renji Hospital affiliated to Shanghai Jiao Tong University
Shanghai, Shanghai, China, 200127
Changhai Hospital affiliated to the second millitary medical university
Shanghai, Shanghai, China, 200433
China, Tianjin
Tianjin Chest Hospital
Tianjin, Tianjin, China, 300051
Teda International Cardiovascular Hospital
Tianjin, Tianjin, China, 300457
China, Zhejiang
The Second Hospital Affiliated to Zhejiang University
Hangzhou, Zhejiang, China, 310009
Sir Run Run Shaw Hospital affiliated to Zhejiang
Hangzhou, Zhejiang, China, 310016
Sponsors and Collaborators
Chinese PLA General Hospital
Layout table for investigator information
Principal Investigator: Yundai Chen, MD Chinese PLA General Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Prof. Yundai Chen, Chinese PLA general hospital Identifier: NCT00926562     History of Changes
Other Study ID Numbers: 14147
First Posted: June 23, 2009    Key Record Dates
Last Update Posted: June 27, 2011
Last Verified: June 2011

Keywords provided by Chinese PLA General Hospital:
Contrast Induced Nephropathy
Cardiac Catheterization

Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Kidney Failure, Chronic
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic